We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Leaders of the House Government Reform Committee want the FTC to launch an inquiry to determine if price gouging is pervasive for U.S. flu vaccine stocks and whether there is any justification for price increases for the vaccine.
Concerned about conflicts of interest in the business practices of pharmaceutical benefit managers (PBMs), a bipartisan group of senators wants the FTC to expand a study by examining deals with drugmakers and the extent to which PBMs pass on financial incentives through the distribution channel.
Legislation pending in California that would require pharmaceutical benefit managers (PBMs) to disclose information about their transactions with drugmakers could raise the cost of drugs, according to recent analysis by the FTC.
Consumer group Public Citizen is calling for a federal investigation into whether four nonprofit seniors groups received $41 million from PhRMA in 2002 to improperly support candidates friendly to the pharmaceutical industry.
Rep. Sherrod Brown (D-Ohio) has asked HHS Secretary Tommy Thompson to reconsider his decision to abide by the National Institutes of Health’s (NIH’s) finding that it would not intervene to authorize generic competition with Abbott Laboratories’ AIDS drug Norvir.
Barr Pharmaceuticals has received a license from drugmaker Cephalon to market a generic version of Cephalon’s cancer pain treatment Actiq (oral transmucosal fentanyl citrate).
Alpharma and OTC drugmaker Perrigo will pay the FTC a combined $6.25 million to settle a complaint that alleged an agreement between the two companies limited competition for OTC pediatric liquid ibuprofen and drove up prices.
AdvaMed has lashed out at the FDA’s proposed direct-to-consumer (DTC) advertising guidances, suggesting that the recommendations go beyond the agency’s regulatory authority by restricting the placement and content of help-seeking and disease awareness communications.
Generic pharmaceutical manufacturer Alpharma and OTC drugmaker Perrigo will pay the FTC a combined $6.25 million to settle a complaint that alleged an agreement between the two companies limited competition for OTC pediatric liquid ibuprofen, drove up prices and violated federal law.
Drugmaker Cephalon has granted generic firm Barr Pharmaceutical a license to manufacture and market a generic version of Cephalon’s cancer pain treatment Actiq, Barr said.